Comprehensive support for trials of any size or complexity whether they originate in Asia or include Asian sites
Almac, a contract development and manufacturing organization, has expanded its clinical services and technologies capabilities in Asia. The expansion includes more "on-the-ground" leadership, technical, project, and operational resources, in the company's established hubs in Singapore and Japan. Almac is opening a secondary packaging facility in Singapore that will open by the end of 2014.
Read the full release here.
Phase III Trial of Keytruda Plus Lynparza for NSCLC Stopped Due to Futility
December 7th 2023KEYLYNK-008 trial finds that Keytruda in combination with chemotherapy followed by Keytruda plus Lynparza did not produce an improved overall survival benefit in patients with metastatic squamous non-small cell lung cancer.
Key Phase III Trial Results Lead to FDA Approval of Fabhalta for Paroxysmal Nocturnal Hemoglobinuria
December 6th 2023Clinical trials demonstrated superiority of Fabhalta to anti-C5s in hemoglobin improvement in the absence of transfusions and transfusion avoidance rate, showing clinically meaningful hemoglobin-level increases without the need for blood transfusions in patients with paroxysmal nocturnal hemoglobinuria.